Fund II – which is the second in the order of Impilo – exceeded the €600 million target, thanks to support from both existing and new investors, including AP1, AP3, AP6, Cubera, Patria Investments and funds managed by BlackRock.
- We are humbled and proud of the strong momentum we have experienced throughout the fundraising process. The speed of the raise is a testament to investors' confidence in Impilo as the only Nordic healthcare-focused manager, says Fredrik Stromholm, Managing Partner at Impilo.
Impilo currently has approximately EUR 2 billion under management, with portfolio companies including Immedica Pharma, Scantox, Stille and Human. Fund II will build on the strategy of investing in Nordic companies within pharmaceuticals, medical technology and healthcare services, with a focus on majority acquisitions of companies that have the potential to double EBITDA in five years.
- The Nordics is home to a thriving, highly innovative healthcare ecosystem with a strong export-driven culture, and with Fund II, we are excited to continue working hand-in-hand with portfolio companies on their internationalization journeys from local champions to global leaders, says Magnus Edlund, Partner.
